The Evidence-based Practice Center Program at the Agency for Healthcare Research and Quality (AHRQ) has posted the draft report for the systematic review on Management of Primary Headaches in Pregnancy. Read more.
Researchers suggest the possibility of an underpinning biological relationship between people with persistent headache and back pain, which could be a target for treatment.
Study Description: Brief Summary: This is a United States Department of Defense funded Focused Program study that aims to identify mechanisms and predictors for persistent of post-traumatic headache attributed to mild traumatic brain injury, and identify methods of preventing post-traumatic headache persistence. The objective of the clinical trial component of the Focused Program is to determine whether intervention with erenumab is an effective treatment for PTH attributed to mTBI.
AbstractObjective: To report a case of petrous apicitis that manifested as chronic migraine without aura and to discuss the pathophysiological mechanisms behind this presentation. Background:Petrous apicitis is a rare complication of acute otitis media with varied clinical presentations that stem from the close proximity of the petrous apex to numerous neurovascular structures. Headache is among the common symptoms of petrous apicitis.
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality® (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults.
© American Academy of Pain Medicine. All Rights Reserved.
American Academy of Pain (AAMP) is a nonprofit, 501(c)(3) tax-exempt organization.
1705 Edgewater Drive, #7778
Orlando, FL 32804
Phone: (800) 917-1619 Ext. 102
Fax: (407) 749-0714
American Academy of Pain Medicine
